Hengchang. Song, K. Yan, X. Xu
Oct 15, 2004
Citations
0
Influential Citations
2
Citations
Journal
Journal of Chromatography B
Abstract
Abstract 5-[2,4-Dioxothiazolidin-5-yl)methyl]-2-methoxy- N -[[(4-trifluoromethyl)-phenyl]methyl]benzamide ( I , MK-0767 or KRP-297, Fig. 1), is a dual α/γ peroxisome proliferator-activated receptor (PPAR) agonist. A LC–MS/MS method for the determination of I in human plasma has been successfully developed, validated and applied to clinical programs. The analyte and internal standard ( II ) are extracted from 0.05 mL plasma via solid phase extraction (SPE). HPLC is used for the separation of I and II from possible co-extracted endogenous and other compounds. Detection is by MS/MS in multiple reaction monitoring (MRM) mode using a TurboIonSpray ® probe. The whole sample preparation is automated by using a Packard Multiprobe liquid handling system. The linear range is 4–2000 ng/mL in plasma. Recoveries were 71.1% and 69.4% for I and II , respectively. The method exhibited good linearity, reproducibility and sensitivity, selectivity and robustness when used for the analysis of clinical samples.